Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Redmile Group, Llc bought 25,700 shares of the business’s stock in a transaction dated Friday, April 14th. The shares were bought at an average price of $6.00 per share, with a total value of $154,200.00. Following the purchase, the director now owns 12,859,119 shares in the company, […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) traded down 4.7% during mid-day trading on Tuesday . The company traded as low as $6.27 and last traded at $6.28. 585,829 shares traded hands during trading, a decline of 84% from the average session volume of 3,674,282 shares. The stock had previously closed at $6.59. […]
Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.